May 5, 2023 07:45 AM EDTUpdated 12:24 PM

Acelyrin's IPO is an 'N of 1', industry insiders say, as 50+ biotechs are still waiting for their moment on the markets

California drug developer Acelyrin landed on the Nasdaq Friday morning in one of the largest biotech debuts since 2021, at

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ace­lyrin's IPO is an 'N of 1', in­dus­try in­sid­ers say, as 50+ biotechs are still wait­ing for their mo­ment on the mar­kets